Raytheon awarded $71 million in Navy contracts for missile systems
Robert L. Van Nostrand, a director at SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), recently acquired 10,000 shares of the company’s common stock. The purchase, which took place on June 12, 2025, was executed at a price of $1.48 per share, totaling $14,800. The stock, currently trading at $1.65, has shown remarkable momentum with an 89% gain over the past six months. According to InvestingPro analysis, analysts have set price targets ranging from $4 to $7.50 for the stock. Following this transaction, Van Nostrand’s direct ownership stands at 20,400 shares. This acquisition reflects a continued investment in the company by its board member. The $165 million market cap company maintains strong liquidity with a current ratio of 4.64, and InvestingPro data shows it holds more cash than debt on its balance sheet. For deeper insights into SLS’s financial health and additional analysis, InvestingPro offers 8 more key tips for investors.
In other recent news, SELLAS Life Sciences Group, Inc. has shared significant updates regarding its cancer therapy developments. The company announced promising results from its Phase 2 trial of SLS009 for relapsed/refractory acute myeloid leukemia (AML), showing a median overall survival of 8.9 months in patients with AML-myelodysplasia-related changes. This is a notable improvement over the historical benchmark of 2.5 months. Additionally, SELLAS presented encouraging preclinical data at the American Society of Clinical Oncology meeting, highlighting SLS009’s efficacy in colorectal cancer cell lines with ASXL1 mutations.
The company has also initiated treatment for the first pediatric patient in a Phase 2 trial of SLS009 for relapsed/refractory AML, emphasizing its commitment to addressing unmet medical needs in hematologic conditions. Furthermore, SELLAS has expanded its Scientific Advisory Board by appointing two oncology specialists, Philip C. Amrein, MD, and Alex Kentsis, MD, PhD, to guide its clinical programs. These developments come as SELLAS anticipates reaching critical points in its clinical trials, including full topline Phase 2 data for SLS009 and the final analysis of the Phase 3 REGAL trial for GPS in AML.
The company has also been granted the FDA Rare Pediatric Disease Designation for SLS009 in treating pediatric AML, which could lead to a Priority Review Voucher if a New Drug Application is approved. SELLAS continues to focus on developing novel therapeutics with its lead product candidates, GPS and SLS009, at the forefront. The ongoing trials aim to evaluate the safety, efficacy, and potential biomarkers for these treatments, with additional cohorts being enrolled to further assess their impact on AML and other cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.